What Happened

On September 22, 2026, Heidi Health Trading Pty Ltd. announced $340 million in total new funding to scale its AI Care Partner platform across global health systems. The round consists of a $100 million Series C led by Blackbird, with participation from existing investors Phoenix Court, Point72 Private Investments, and Headline, plus $240 million in growth investment from General Catalyst.

Founded in Melbourne, Australia, by Dr. Thomas Kelly, Heidi Health has built a suite of clinical AI tools. Its core product, Scribe, performs ambient listening to record patient history and symptoms, update records, provide multilingual support, and prepare coding suggestions and documentation. In March 2026, the company launched Evidence, a point-of-care research tool that factors in active patient details, lab results, and live conversation transcripts to generate summaries with in-line citations and risk scoring. Evidence has reportedly answered more than 10 million queries since launch.

Heidi has also shipped Remote, a secure wearable device for clinical settings from surgery to community clinics, and Dictate, a voice-to-text feature.

Confirmed deployments include Beth Israel Lahey Health in Massachusetts and NHS England Midlands, where Heidi was selected as sole supplier — described as the largest clinical AI procurement in NHS history. The company reports a 62% enterprise activation rate across major public and private health systems since its Series B in October 2025.

Why It Matters

This funding round is a signal that vertical AI agents in healthcare are transitioning from pilot programs to standardized procurement. The $240M growth component from General Catalyst is particularly telling — it's not early-stage R&D money. It's scale capital, meant to deepen adoption in systems that are already deploying.

The 62% activation rate since October 2025 is a meaningful operational metric. It suggests that once health systems deploy Heidi's ambient AI tools, they stick. For competitors, that's a warning: the ambient scribe category may be consolidating faster than expected, and the NHS sole-supplier deal accelerates that dynamic by demonstrating that public health systems are willing to standardize on a single vendor.

This also fits a broader pattern in the AI agent funding wave. Norm Ai raised $120M in July for legal AI agents. HappyRobot raised $150M in August for enterprise AI agents. But Heidi's $340M — particularly the growth check — indicates that healthcare verticals may attract larger capital pools than horizontal agent platforms, likely because the regulatory complexity and procurement cycles create higher barriers and therefore more defensible positions once a vendor is in.

The AMA's finding that 81% of physicians are using augmented AI in 2026 (more than double the 2023 rate) provides macro-level tailwind context. Adoption is no longer the question — vendor selection is.

Who Is Affected

Healthcare AI startups building ambient scribing, clinical documentation, or point-of-care research tools now face a well-capitalized competitor with major system contracts and demonstrated stickiness. The ambient scribe category (Abridge, Suki, Nabla, Heidi) is entering a phase where distribution and deployment depth matter more than feature parity.

Clinical informatics and IT leaders at U.S. and U.K. health systems should evaluate Heidi's platform against alternatives, paying particular attention to the activation and retention metrics rather than feature checklists. The NHS sole-supplier precedent is worth studying for procurement strategy.

Investors tracking AI agent deployments should note that healthcare verticals are attracting growth-stage capital at scale, potentially outpacing horizontal agent platforms in deal size.

Strategic Implications

For AI startup founders: If you're building in healthcare AI, the ambient scribing wedge is becoming crowded and capital-defended. Differentiation now requires adjacent capabilities — specialty-specific workflows, evidence retrieval with citations, wearable integration, or multi-language support at scale — that incumbents haven't fully dominated yet. The window is narrowing.

For developers/operators building with AI APIs: Heidi's Evidence product (10M+ queries since March) validates that clinicians will adopt AI-powered research tools when they include in-line citations, risk scoring, and integration with live patient data. If you're building clinical-adjacent AI applications, these features are becoming table stakes, not differentiators.

For non-technical business owners evaluating AI tools: The 62% activation rate and NHS sole-supplier deal are the metrics that matter. When evaluating any clinical AI vendor, ask for activation rates, retention data, and deployment depth — not just feature lists. A vendor with 100 features and 20% activation is less valuable than one with 5 features and 62% activation.

What to Watch Next

Monitor whether Heidi's growth capital translates into U.S. market share gains against Abridge and Suki, and whether the NHS sole-supplier model gets replicated in other public health systems. Also watch for whether competitors respond with their own growth rounds — the ambient scribe category may see consolidation within 12 months.

Frequently Asked Questions

Q: How much did Heidi Health raise and from whom?

A: Heidi Health raised $340 million in total, comprising a $100 million Series C led by Blackbird (with participation from Phoenix Court, Point72 Private Investments, and Headline) and $240 million in growth investment from General Catalyst, announced on September 22, 2026.

Q: What products does Heidi Health offer?

A: Heidi's platform includes Scribe (ambient clinical documentation), Evidence (point-of-care medical research with in-line citations and risk scoring), Remote (a secure wearable for clinical settings), and Dictate (voice-to-text). Evidence has answered over 10 million queries since its March 2026 launch.

Q: Which health systems use Heidi Health?

A: Confirmed deployments include Beth Israel Lahey Health in Massachusetts and NHS England Midlands, where Heidi was selected as sole supplier in what the company describes as the largest clinical AI procurement in NHS history. The company reports 62% enterprise activation across major public and private health systems since its October 2025 Series B.